Intangible asset and goodwill impairment testing for a publicly-traded biopharmaceutical company

Intangible asset and goodwill impairment testing for a publicly-traded biopharmaceutical company

Life Sciences | Pharmaceuticals
Intellectual Property

A publicly-traded biopharmaceutical company, which had just emerged out of bankruptcy protection, retained CRA to conduct its intangible asset and goodwill impairment testing. First, CRA performed a ASC 360 recoverability test of the company’s intangible asset group, which included distribution agreements, customer relationships, non-compete agreements, and trade name. CRA then conducted a ASC 350 goodwill impairment analysis, which included both a comparison of the company’s carrying value with its fair value as well as a hypothetical purchase price allocation, to determine the goodwill impairment loss.